VisEn Medical Launches Expanded FMT 2500(TM) Imaging Platforms at AACR Meeting
FMT(TM) Quantitative Tomographic Imaging Being Expanded to Four Fluorescent Channels to Enable Greater Data Ranges and Multiplexing of Disease Biomarkers In Vivo
VisEn Multi-Modality Imaging Adapter Series Launched to Enable Imaging, Co-Registration and Data Fusion Between FMT and CT, MR, Sp...
Telik Announces Preclinical Presentations at AACR Annual Meeting
PALO ALTO, Calif., April 14 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) announced today that two abstracts highlighting results from its Research and Development programs will be presented at the 100th annual meeting of the American Association for Cancer Research (AACR) in Denver, CO....
The AACR commends Senators Kennedy and Hutchison on the 21st Century Cancer ALERT Act
PHILADELPHIA ― On Thursday, Senators Edward M. Kennedy and Kay Bailey Hutchison introduced legislation that will renew the war on cancer by modernizing and advancing the national cancer program of the United States.
The 21st Century Cancer ALERT (Access to Life-saving Early detection, Res...
Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009
SAN DIEGO, Feb. 17 /PRNewswire/ -- Tracon Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that its three clinical stage cancer therapeutics (TRC105, TRC102, and TRC093) will be presented at the 100th Annual Meeting of the...
Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference
DALLAS, April 10 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.
(OTC Bulletin Board: ACCP) announced today that its collaborators at
prestigious institutes in France and Italy will be presenting new
preclinical data on its lead anticancer compound, ProLindac(TM), at the
Telik Announces Preclinical Presentations at AACR Annual Meeting
PALO ALTO, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Telik, Inc.
(Nasdaq: TELK ) announced that four abstracts highlighting results from its
Research and Development programs will be presented at the 99th annual
meeting of the American Association for Cancer Research (AACR) in San
Bernstein honored with AACR Prevention Award
PHILADELPHIA Leslie Bernstein, Ph.D., a research expert on the effects of hormones and physical activity on cancer risk, late effects of cancer treatment, the impact of lifestyle on cancer prognosis, and quality of life after cancer, has been selected to receive the sixth annual American Associat...
Emerging therapies with a focus on Asian populations mark the AACR Centennial Conference
SINGAPORE -- To mark its 100th year of advancing cancer research, the American Association for Cancer Research is holding Centennial Conferences in North America, Europe, and Asia. The AACR
has teamed with the Genome Institute of Singapore and Singapores Agency for Science, Technology and Researc...
NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR
DENVER and SAN CARLOS, Calif., April 22 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) presented data today at the American Association for Cancer Research (AACR) 100th Annual Meeting demonstrating that NKTR-105, a novel PEGylated form of docetaxel, has superior antitumor activity...
Micromet, Inc. Reports Second Quarter 2009 Financial Results
... BRAF-mutated human colorectal cancer cells at the aacr
meeting. The non-clinical data indicated that Mic...al antibodies. Micromet also presented data at the aacr
meeting indicating that its BiTE antibody MT110 ca...ts on its BiTE antibody pipeline and to review key aacr
On June 1, Mic...
AACR in Medical Technology
Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
Pivotal Trial Expected to Initiate in 2010 for Blinatumomab
NEW YORK, April 24 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today held an R&am...
Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model
-Preclinical Results Further Validate Significant Anti-Tumor Potential of Fully Human Anti-PS Antibodies and Expand the Company's PS-Targeting Platform-
-Treatment with Mouse Equivalent to the Human Antibody Inhibited Tumor Growth in a Prostate Cancer Model by More than 90%-
Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies
- Preclinical Studies Highlight the Ability of PS-Targeting Antibodies to Reverse the Immune Suppressing Effects of Tumors by Changing the Tumor Microenvironment and Mobilizing Key Components of the Immune System -
- Studies Confirm Peregrine's PS-Targeting Antibodies Stimulate Dendritic C...
Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
SAN DIEGO, April 17 /PRNewswire/ -- Cylene Pharmaceuticals announced today that it will be presenting new data on recent advances of its small molecule anticancer agents during a symposium and several poster presentations at the American Association for Cancer Research (AACR) annual meeting, to be...
EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Compounds Demonstrate Potent Antitumor Activity in a Variety of Tumor Types
ROCKVILLE, Md., April 16 /PRNewswire-FirstCall/ -- EntreMed, Inc.
(Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing
therapeutics for the treatment of cancer and inflammatory diseases, today
Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
SAN DIEGO and SUNNYVALE, Calif., April 15 /PRNewswire-FirstCall/ --
Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced preclinical data from
four presentations at the Annual Meeting of the American Association for
Cancer Research (AACR) being held this week in San Diego, CA. Results from
Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
- Bavituximab Causes Pro-Inflammatory Effects in the Tumor Microenvironment That May Contribute to Its Anti-Tumor Efficacy - - Studies Show Similar Results for a New Fully Human Version of the Antibody -
SAN DIEGO and TUSTIN, Calif., April 15 /PRNewswire...
Preclinical Study Presented at AACR Annual Meeting Shows Peregrine's Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
- 80% of Subjects Immunized with Anti-PS Immunocytokines and Irradiated
Tumor Cells Achieved Long-Term Survival Compared to Just 20% of Controls - - Data Highlights Broad Anti-Cancer Potential of Peregrine's Anti-PS Vascular Targeting Antibodies -
SAN DIEGO and TUSTIN, Cal...
Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
-No Metastatic Lesions Were Detectable After Combination Therapy Treatment- -Survival Time More Than Doubled in Animals Treated with Combination Therapy-
-Established Tumors Regressed by 50% After Combination Therapy Treatment-
SAN DIEGO and TUSTIN, Calif., April...
Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies
-Combination of a Bavituximab Equivalent and an Agent that Re-Activates the
Tumor Suppressor P53 Inhibited Tumor Growth Synergistically in Preclinical Breast Cancer Models-
SAN DIEGO and TUSTIN, Calif., April 14 /PRNewswire-FirstCall/ --
Peregrine Pharmaceuticals, Inc. (...
AACR in Biological News
Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies
DENVER, Colorado and TUSTIN, Calif., April 21, 2009--Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today reported that two preclinical studies presented during th...
Burnham researchers present at 100th AACR Meeting
LA JOLLA, Calif., April 17, 2009 -- Burnham Institute for Medical Research (Burnham) is pleased to announce that five of its postdoctoral fellows will present seven papers on their data at the American Association for Cancer Research (AACR) 100th Annual Meeting 2009. In addition, John C. Reed, M.D...
Easton honored with inaugural AACR Outstanding Investigator Award in Breast Cancer Research
SAN ANTONIO Douglas Easton, Ph.D., whose international studies in breast cancer explained the genetic patterns and causes of the BRCA1 and BRCA2 gene mutations which indicate a person's risk for breast cancer, has been selected to receive the inaugural American Association for Cancer Research (AA...
Massague honored with inaugural AACR Distinguished Leadership Award in Breast Cancer Research
SAN ANTONIO Joan Massagu, Ph.D., whose research identified the role of transforming growth hormone factor-Beta (TGF-Beta) in the metastasis of breast cancer cells to the lung, has been selected to receive the inaugural AACR
Distinguished Leadership Award in Breast Cancer Research.
AACR applauds nomination of Francis S. Collins, M.D., Ph.D., to be the new NIH director
...Dr. Collins' experience and insight will be invaluable," said Jacks.
looks forward to working with Dr. Collins as new scientific discoveries transform the prevention, diagnosis and treatment of cancer. The aacr
urges the Senate to confirm him with haste.
M. D. Anderson gives first Margaret Kripke Legend Award to Margaret Foti
...ed Women in Cancer Research (WICR), a group within aacr
that supports the professional advancement and sci...he true pioneers in this area."
Foti started at aacr
as editorial assistant for the journal Cancer Rese...ive director of the AACR.
Under her leadership, aacr
has grown on all fronts. The association has added...
The American Association for Cancer Research congratulates Margaret Hamburg, M.D.
...s well as efforts to develop the next generation of clinical trials.
is confident that she will provide the expertise, integrity and leadership ... advances in the causes, diagnosis, treatment and prevention of cancer, the aacr
looks forward to working with Hamburg as a resource to ensure the FDA maint...
American Association for Cancer Research hosts Science of Health Care Disparities Meeting
...schedule is available online at www.aacr.org . The aacr
will be hosting daily press briefings, and informa...ere:
Carefree Resort and Villas
Location: Cholla II
Hours: 8:00 a...page15020.aspx
Deadline for registering for the aacr
housing block is January 12, 2009
AACR to host Seventh Annual International Conference on Frontiers in Cancer Prevention Research
...in a variety of disciplines, to discuss the latest findings in the field and to stimulate the development of new research in cancer prevention.
will host six press briefings for reporters during the conference that will include breaking news:
A groundbreaking scientific partnership with...
CTRC-AACR San Antonio Breast Cancer Symposium
... will be the first Symposium presented by the CTRC (Cancer Therapy & Research Center) at the University of Texas Health Science Center at San Antonio, aacr
and the Baylor College of Medicine. More than 1,000 abstracts will be presented at the symposium, complementing an outstanding program of scientific a...
AACR in Biological Technology
Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
BONITA SPRINGS, Fla., April 30 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, announced that preclinical data were presented on its novel molecule, AFP-464, during the recent AACR
100th Annual Meeting 2009 in Denver. "This research represents a significan...
Telik Reports Preclinical Results at AACR Annual Meeting
PALO ALTO, Calif., April 28 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) announced results of studies on two of its drug development programs that were presented at the 100th annual meeting of the American Association for Cancer Research (AACR) in Denver, CO. The abstracts can be found...
AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
QUEBEC CITY, April 22 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ), a global biopharmaceutical company focused on endocrine therapy and oncology, today presented a poster outlining Phase 1 results for its orally-active tubulin and topoisomerase II inhibitor compound, ...
Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
DENVER , April 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, yesterday presented data at the annual meeting of the American Association for Canc...
AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
In Vitro and In Vivo Data Show AEZS-126 as Promising Oral Compound for
Future Clinical Development in Cancer
QUEBEC CITY, April 21 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS ), a global biopharmaceutical company focused on endocrine therapy and oncology, today ...
Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting
- Data demonstrates that ProLindac should provide sustained tumor exposure to platinum and provides a mechanistic rationale for the low hematoxicity observed in the clinic -
DALLAS, April 21 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today ...
Cytopia Presentation on VDA CYT997 at AACR Conference
MELBOURNE, Australia, April 15 /PRNewswire/ -- Cytopia Limited (ASX: CYT) announced that it will present data on its anticancer vascular disrupting agent (VDA) CYT997 at the forthcoming 100th Annual Meeting of the American Association for Cancer Research, in Denver, Colorado, USA.
Dr David S...
AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
QUEBEC CITY, April 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it will present two posters on its PI3K inhibitor compound, AEZS-126, as well as a poster on its oral...
Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
CALGARY, March 16 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) announced today that abstracts covering research with reovirus (REOLYSIN(R)) are available on the American Association for Cancer Research (AACR) website at www.aacr.org , and on the Oncolytics website ...
ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
Three Developmental Compounds Show Early Promise
MONTREAL, April 17 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc.
(TSX:PLI) ("ProMetic") announced results of three compounds in preclinical
studies for prostate and pancreatic cancer at the American Association for